Avalo Therapeutics (AVTX) Net Income (2014 - 2026)
Avalo Therapeutics (AVTX) reported Net Income of -$19.6 million for Q1 2026, down 49.29% on a YoY basis from -$38.7 million in Q1 2025, and down 43.08% quarter-over-quarter from -$13.7 million in Q4 2025.
Avalo Therapeutics (AVTX) Net Income (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Net Income for 12 years, with the latest figure at -$19.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income fell 49.29% year-over-year to -$19.6 million; the trailing twelve-month figure through Mar 2026 stood at -$84.7 million (down 216.06% YoY), and the FY2025 full-year result was -$78.3 million, down 122.78% from the prior year.
- Net Income for Q1 2026 stood at -$19.6 million, down from -$13.7 million in the prior quarter.
- The five-year high for Net Income was $98.5 million in Q2 2024, with the low at -$121.3 million in Q1 2024.
- Historically, Net Income has averaged -$12.7 million across 4 years, with a median of -$13.1 million in 2025.
- The largest YoY upside for Net Income was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
- Avalo Therapeutics' Net Income stood at -$8.2 million in 2023, then sank by 332.65% to -$35.3 million in 2024, then surged by 61.18% to -$13.7 million in 2025, then plunged by 43.08% to -$19.6 million in 2026.
- The last three Net Income figures came in at -$19.6 million (Q1 2026), -$13.7 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -13.72 Mn |
| Sep 30, 2025 | -30.63 Mn |
| Jun 30, 2025 | -20.77 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -8.17 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2021 | -65,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Jun 30, 2021 | 69,000.00 |
| Mar 31, 2021 | -106,000.00 |
| Dec 31, 2020 | 499,000.00 |
| Sep 30, 2020 | -198,000.00 |
| Jun 30, 2020 | -455,000.00 |